BioNTech mRNA Cancer Trial Misses Goal
BioNTech announced its experimental mRNA cancer immunotherapy failed to meet the primary goal in a mid-to-late-stage trial for head and neck cancer. Shares fell nearly three percent in early trading following the news. The trial will continue to evaluate overall survival as its secondary endpoint.
Xurve View
Insights:
Xurve View
BioNTech SE saw its experimental mRNA cancer therapy miss its primary progression-free survival target in an advanced head and neck cancer trial. United States-listed shares fell 3% in early trading following the announcement. The setback tests the limits of combining customized mRNA vaccines with established checkpoint inhibitors.
